Synovo was in ARVO
Did you meet us in the Association for Research in Vision and Ophthalmology (ARVO), 7-11 May 2017 in Baltimore?
Would you like to know more about our ophthalmology program?
Contact us in firstname.lastname@example.org
Synovo is committed to develop the in-house research line for infectious diseases.
Synovo’s presence in the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Synovo GmbH and Qualizyme diagnostics collaboration:
Finalists for the Better Use of Antibiotics Prize
An innovative detection system for airway infections developed by the collaboration between Synovo GmbH and Qualizyme diagnostics within the top 3 finalists for the Better Use of Antibiotics Prize by the European Commission.
The FOLSMART Kick-off meeting took place in Brussels last week.
FOLSMART, Folate-Target Nanodevices To Activated Macrophages For Rheumatoid Arthritis, granted by the European Commission within the Horizon 2020.
Synovo GmbH holds DIN EN ISO 9001 certification.
Synovo GmbH has been certified for the worldwide accepted quality standard DIN EN ISO 9001.
Thank you and congratulations to the Synovo team.
Synovo expands business to ophthalmology
Tübingen, Germany, February 2014. Synovo, a company focused on drug discovery and preclinical development, today announced the strategic decision to extend its service portfolio on ophthalmic indications.
Synovo wird Anbieter für Dienstleistungen und Lösungen für Forschung und Entwicklung in der Augenheilkunde
Tübingen, Februar 2014. Synovo, Spezialist für Identifikation und präklinische Entwicklung neuer Medikamente, kündigte heute eine strategische Erweiterung seines Portfolios auf den Bereich Augenheilkunde an.
10 years of Synovo
Synovo 10 years anniversary on Nov 2014 was a total success.
On 20 October 2014, orphan designation was granted by the US Food and Drug Administration (FDA) to Synovo GmbH, Germany, for its oncology candidate for the treatment of pancreatic cancer.
On 22 August 2014, orphan designation (EU/3/14/1323) was granted by the European Medicines Agency (EMA) to Synovo GmbH, Germany, for its oncology candidate for the treatment of pancreatic cancer.
On 19 February 2014, orphan designation (EU/3/14/1239) was granted by the European Medicines Agency (EMA) to Synovo GmbH, Germany, for its CF candidate for the treatment of cystic fibrosis.